09:02 AM EDT, 04/17/2026 (MT Newswires) -- Gilead Sciences ( GILD ) said Friday it has received all the regulatory approvals required for its previously announced acquisition of Arcellx.

The Australian Competition and Consumer Commission published its decision on Monday that the acquisition may be put into effect, subject to a 14-calendar day waiting period, Gilead Sciences ( GILD ) said.

Gilead also said it has extended its tender offer to purchase all outstanding common shares of Arcellx to April 27 from April 24.

Gilead is offering $115 in cash for each Arcellx share, plus one contractual contingent value right, representing $5 in cash, contingent on worldwide sales of Arcellx's anitocabtagene autoleucel exceeding $6 billion on or prior to Dec. 31, 2029, according to the company.